{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:59:20Z","timestamp":1790625560290,"version":"4.1.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EA Pharma Co., Ltd"},{"name":"Kissei Pharmaceutical Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carotegrast methyl is an oral \u03b14-integrin antagonist used to induce remission in patients with ulcerative colitis with an inadequate response to 5-aminosalicylate (5-ASA). This multicenter, retrospective observational study evaluated the clinical usefulness of carotegrast methyl in real-world practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with an inadequate response to 5-ASA who received carotegrast methyl were included. Clinical data were collected during and after treatment for up to 52\u2009weeks. The primary endpoint was the response rate at week 8. The remission rate at week 8, response\/remission rate at end of treatment, cumulative response\/remission rate, and adverse drug reactions were also assessed. Effectiveness was evaluated using the patient reported outcomes-2 measure (sum of Mayo subscores for stool frequency and rectal bleeding).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data were collected from 196 patients, of whom 180 were evaluable for effectiveness. The PRO-2-defined response and remission rates at week 8 were 57.8% and 43.3%, respectively, and the rates at the end of treatment (median treatment duration: 83.5\u2009days) were 58.9% and 50.0%, respectively. The cumulative PRO-2-defined response\/remission rates increased until week 16, followed by a slight further increase. Adverse drug reactions occurred in 31 of 196 patients (15.8%, 43 events), with no serious events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In terms of patient-reported symptom improvement, carotegrast methyl is an effective and well-tolerated treatment for patients with ulcerative colitis who have an inadequate response to 5-ASA. A substantial proportion of patients responded to 8\u2009weeks of treatment. Continued treatment for up to 16\u2009weeks may improve symptoms, even in patients with insufficient response at week 8.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag194","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:20:03Z","timestamp":1789384803000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness, safety, and clinical outcomes of treatment with the oral \u03b14-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study)"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-5675","authenticated-orcid":false,"given":"Fumihito","family":"Hirai","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Fukuoka University Faculty of Medicine , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-7660","authenticated-orcid":false,"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center , Sakura,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3781-4724","authenticated-orcid":false,"given":"Kenji","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine for Inflammatory Bowel Disease, University of Toyama , Toyama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8511-2540","authenticated-orcid":false,"given":"Ryota","family":"Hokari","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Defense Medical College , Tokorozawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8172-3240","authenticated-orcid":false,"given":"Masayuki","family":"Saruta","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2848-6586","authenticated-orcid":false,"given":"Hiroshi","family":"Nakase","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7551-5568","authenticated-orcid":false,"given":"Takayuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Yokkaichi Hazu Medical Center , Yokkaichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-8841","authenticated-orcid":false,"given":"Mao","family":"Matsubayashi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7047-571X","authenticated-orcid":false,"given":"Ryuichi","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Institute of Science Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-618X","authenticated-orcid":false,"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hyogo Medical University School of Medicine , Nishinomiya,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-3243","authenticated-orcid":false,"given":"Makoto","family":"Naganuma","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Kansai Medical University , Hirakata,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6060-588X","authenticated-orcid":false,"given":"Hitoshi","family":"Hongo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fujita Gastroenterological Hospital , Takatsuki,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5419-6669","authenticated-orcid":false,"given":"Hirozumi","family":"Obata","sequence":"additional","affiliation":[{"name":"Obata Medical Clinic , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6449-8392","authenticated-orcid":false,"given":"Katsuya","family":"Endo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku Medical and Pharmaceutical University , Sendai,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3196-2558","authenticated-orcid":false,"given":"Akihiro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center , Sakura,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2530-760X","authenticated-orcid":false,"given":"Shinya","family":"Ashizuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukuoka University Faculty of Medicine , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-5169","authenticated-orcid":false,"given":"Noritaka","family":"Takatsu","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital , Chikushino,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7550-0841","authenticated-orcid":false,"given":"Toshiyuki","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ishida","sequence":"additional","affiliation":[{"name":"Ishida Clinic of IBD and Gastroenterology , Oita,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1869-2135","authenticated-orcid":false,"given":"Jun","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-1594","authenticated-orcid":false,"given":"Masayuki","family":"Fukata","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Disease, Division of Gastroenterology, Department of Internal Medicine, Tokyo Yamate Medical Center , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takashima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine for Inflammatory Bowel Disease, University of Toyama , Toyama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7275-8009","authenticated-orcid":false,"given":"Yoshiyuki","family":"Hosoi","sequence":"additional","affiliation":[{"name":"EA Pharma Co., Ltd , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2054-394X","authenticated-orcid":false,"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"EA Pharma Co., Ltd , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0025-6707","authenticated-orcid":false,"given":"Gakuto","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Kissei Pharmaceutical Co., Ltd , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-1204","authenticated-orcid":false,"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[{"name":"Keio University , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5475-9544","authenticated-orcid":false,"given":"Mamoru","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Organoid Center, Graduate School of Medicine, Juntendo University , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyorin University School of Medicine , Mitaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2026092815150342500_izag194-B1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026092815150342500_izag194-B2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"2026092815150342500_izag194-B3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41575-022-00738-z","article-title":"Improving IBD outcomes in the era of many treatment options","volume":"20","author":"Kobayashi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026092815150342500_izag194-B4","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2024.08.003","article-title":"Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments","volume":"45","author":"Wangchuk","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"2026092815150342500_izag194-B5","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1016\/j.crohns.2013.03.014","article-title":"Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice","volume":"7","author":"Sugiura","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2026092815150342500_izag194-B6","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"2026092815150342500_izag194-B7","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S2468-1253(22)00022-X","article-title":"AJM300 (carotegrast methyl), an oral antagonist of \u03b14-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"7","author":"Matsuoka","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026092815150342500_izag194-B8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.5217\/ir.2025.00066","article-title":"Real-world effectiveness and safety of carotegrast methyl in patients with ulcerative colitis: a multicenter retrospective cohort study","volume":"24","author":"Koshiba","year":"2026","journal-title":"Intest Res"},{"key":"2026092815150342500_izag194-B9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2026092815150342500_izag194-B10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026092815150342500_izag194-B11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/ecco-jcc\/jjac182","article-title":"Mucosal addressin cell adhesion molecule 1 expression reflects mucosal inflammation and subsequent relapse in patients with ulcerative colitis","volume":"17","author":"Uchiyama","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026092815150342500_izag194-B12","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1111\/jgh.17000","article-title":"Association of vascular cell adhesion molecule-1 expression in colonic mucosa with mucosal inflammation and subsequent relapse in patients with ulcerative colitis","volume":"40","author":"Takagi","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"2026092815150342500_izag194-B13","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00535-025-02299-9","article-title":"Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)","volume":"60","author":"Matsuoka","year":"2025","journal-title":"J Gastroenterol"},{"key":"2026092815150342500_izag194-B14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000541663","article-title":"Real-world effectiveness and safety of carotegrast methyl in Japanese patients with moderately active ulcerative colitis","volume":"9","author":"Ohmori","year":"2024","journal-title":"Inflamm Intest Dis"},{"key":"2026092815150342500_izag194-B15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5217\/ir.2025.00046","article-title":"Efficacy and safety of carotegrast methyl in active ulcerative colitis: a real-world prospective cohort study","volume":"24","author":"Shimoyama","year":"2026","journal-title":"Intest Res"},{"key":"2026092815150342500_izag194-B16","doi-asserted-by":"publisher","first-page":"2065383","DOI":"10.1155\/2020\/2065383","article-title":"Correlation of patient-reported outcome (PRO-2) with endoscopic and histological features in ulcerative colitis and Crohn\u2019s disease patients","volume":"2020","author":"Dragasevic","year":"2020","journal-title":"Gastroenterol Res Pract"},{"key":"2026092815150342500_izag194-B17","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1007\/s10620-021-07178-w","article-title":"Patient-reported outcome and clinical scores are equally accurate in predicting mucosal healing in ulcerative colitis: a prospective study","volume":"67","author":"Golovics","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2026092815150342500_izag194-B18","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.3390\/jcm14134733","article-title":"Objective treatment targets and their correlation with patient-reported outcomes in inflammatory bowel disease: a real-world study","volume":"14","author":"Wetwittayakhlang","year":"2025","journal-title":"J Clin Med"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag194\/71446280\/izag194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag194\/71446280\/izag194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:20:52Z","timestamp":1790623252000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag194\/8842576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":18,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag194","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"izag194"}}